Clinical Challenges of Immune Checkpoint Inhibitors

Title
Clinical Challenges of Immune Checkpoint Inhibitors
Authors
Keywords
immunotherapy, PD-1, PD-L1, CTLA-4, hyperprogression, pseudoprogression, treatment-limiting toxicity, optimal immunological dose, time-dependent endpoints, clinical trial design
Journal
CANCER CELL
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2020-08-03
DOI
10.1016/j.ccell.2020.07.004

Ask authors/readers for more resources

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now